- Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
-
Nishikawa , Hasegawa K, Yabuno A, Yoshida H, Yasuda M, Kozawa E, Fujiwara K
- KMID: 2413861
- J Gynecol Oncol.
- 2017 Jan;28(1):e25.
- doi: 10.3802/jgo.2017.28.e25
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase II Study of Cetuximab (Erbitux(R)) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
-
Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, Kim MK, Sym SJ, Lee JS, Kang YK
- KMID: 1785796
- J Korean Med Sci.
- 2007 Sep;22(Suppl):S98-S103.
- doi: 10.3346/jkms.2007.22.S.S98
We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were... -
- CITED
-
- Close
- SHARE
-
- Close
- Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
-
Ko YH, Lee MA, Hong YS, Lee KS, Park HJ, Yoo IR, Kim YS, Kim YK, Jo KH, Wang YP, Lee KY, Kang JH
- KMID: 1785624
- Korean J Intern Med.
- 2007 Sep;22(3):178-185.
- doi: 10.3904/kjim.2007.22.3.178
BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is... -
- CITED
-
- Close
- SHARE
-
- Close
- Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization
-
Sung PS, Bae SH, Jang JW, Song DS, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK
- KMID: 1792608
- Korean J Hepatol.
- 2011 Dec;17(4):299-306.
- doi: 10.3350/kjhep.2011.17.4.299
BACKGROUND/AIMS: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Outcome of Transcatheter Arterial Chemoinfusion According to Anticancer Agents and Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma (TNM Stage IVa)
-
Ahn SH, Han KH, Park JY, Youn YH, Moon CM, Lee KS, Chon CY, Moon YM, Lee DY, Lee JT
- KMID: 1103907
- Yonsei Med J.
- 2004 Oct;45(5):847-858.
- doi: 10.3349/ymj.2004.45.5.847
Transcatheter arterial chemoinfusion (TACI) is the main treatment modality for advanced hepatocellular carcinoma (HCC). However, the therapeutic efficacy of TACI according to anti-cancer agents and prognostic factors for advanced HCC... -
- CITED
-
- Close
- SHARE
-
- Close
